Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma
JCO Precision Oncology · 2025
DOI: 10.1200/po-25-00200 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Davidson Zhao und 20 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre-University Health Network, Toronto, Canada. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Whole Genome Sequencing, Cell-Free Nucleic Acids, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Although deep targeted DNA sequencing of liquid biopsies has shown prognostic utility in large B-cell lymphoma (LBCL), the routine clinical adoption of these assays remains limited because of their high costs. MATERIALS AND METHODS Here, leveraging a well-annotated cohort encompassing both frontline and relapsed/refractory (R/R) LBCL, we profiled patient plasma samples with two complementary modalities—ultra-low-pass whole-genome sequencing (ULP-WGS) and deep targeted DNA sequencing, the former being a cost-effective method to profile large scale chromosomal abnormalities and estimate tumor burden. RESULTS Our findings revealed a strong association of high cell-free tumor burden by both genomic profiling modalities with established measures of tumor burden and patient survival. Notably, the associations with survival remained statistically significant after accounting for international prognostic index scoring. Furthermore, we showed that del(17p) in circulating tumor DNA as detected by ULP-WGS was strongly associated with TP53 mutation status and predicted for significantly inferior outcome in frontline LBCL patients but not in patients with R/R LBCL. CONCLUSION Our study demonstrates that ULP-WGS can provide robust prognostic biomarkers for both frontline and R/R LBCL, highlighting its broad applicability for risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre-University Health Network, Toronto, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Canada.
- Hôpitaux Universitaires de Genève, Geneva, Switzerland.
- Ontario Institute for Cancer Research, Toronto, Canada.
ORCID-Profile: Davidson Zhao, Noémie Lang, Ting Liu, Juan Rangel-Patiño, Anthea Travas, Vanessa Murad, Ur Metser, Vishal Kukreti, Abi Vijenthira, Andrea Arruda, Robert Kridel
Zitieren
APA
Zhao, D., Lang, N., Liu, T., Shelton, V., Rangel-Patiño, J., Gong, I. Y., Hong, M., Travas, A., Murad, V., Alrekhais, I., Metser, U., Prica, A., Kukreti, V., Bhella, S., Vijenthira, A., Crump, M., Kuruvilla, J., Arruda, A., Minden, M. D., …, & Kridel, R. (2025). Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma. JCO Precision Oncology. https://doi.org/10.1200/po-25-00200
Vancouver
Zhao D, Lang N, Liu T, Shelton V, Rangel-Patiño J, Gong IY, et al. Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma. JCO Precision Oncology. 2025. doi:10.1200/po-25-00200
BibTeX
@article{Zhao2025,
author = {Zhao, Davidson and Lang, Noémie and Liu, Ting and Shelton, Victoria and Rangel-Patiño, Juan and Gong, Inna Y and Hong, Michael and Travas, Anthea and Murad, Vanessa and Alrekhais, Ibrahim and Metser, Ur and Prica, Anca and Kukreti, Vishal and Bhella, Sita and Vijenthira, Abi and Crump, Michael and Kuruvilla, John and Arruda, Andrea and Minden, Mark D and Lam, Bernard and Kridel, Robert},
title = {Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-25-00200}
}
EUVIMED